This drug effectively reduces LDL cholesterol, total cholesterol, and plasma APOB levels, but it is only approved for patients with homozygous familial hypercholesterolemia, whose plasma cholesterol and TG levels are up to four times the normal levels resulting in premature cardiovascular disease [89–91]. Here, APOB is linked to familial hypercholesterolemia.